Special Announcement - Now Screening for FDA Approved Stem Cell Study
Dr. Mitchell Sheinkop has completed training and is credentialed for an FDA-approved stem cell clinical trial for knee arthritis. Our clinic is now screening patients for this trial. Contact us at 312-475-1893 for details. Click here to learn more.

Most readers know that I “graduated” from joint replacement surgery into an emerging field of Regenerative Medicine about five years ago. Prior to that time, I had dedicated 37 years to Reconstructive Orthopedic Surgery and played an active role in a joint replacement practice combining research with education as I improved the quality of life for my patients. By the end of my surgical career, I had authored more than 90 scientific papers in the field of hip and knee replacement as well serving in the leadership of the joint replacement program at a major medical center in Chicago.

That was “back in the day” of joint replacement surgery; but rather than live in the past, I have elected to partake in the present and advance Cellular Orthopedics into the future. I now have the largest and most comprehensive clinical outcomes data base in the United States concerning Bone Marrow Concentrate, Mechanical preparation of Adipose Graft, and Amniotic Fluid injection used in the treatment of knee arthritis. This information has allowed me, up until now, to make a scientifically based recommendation as to the best regenerative option for dealing with an arthritic joint.

In my initiative to advance the discipline of Cellular Orthopedics, the next innovation will be to offer a prior analysis of the stem cell content for the patient seeking the regenerative option as a means of postponing or avoiding a joint replacement. Should a patient present with osteoarthritis seeking to determine if she, he or hir will benefit from Adult Mesenchymal Stem Cells and Growth Factors, I am able to offer the equivalent of a bone marrow biopsy and determine the amount of viable cellular orthopedic content available in that individual’s bone marrow. My recommendations then would be based on actual number of cells and not on age related or disease influenced averages or estimates. Predictability of an individual’s outcome in determining whether to proceed with the regenerative intervention would be customized and not generalized. Where this scientific leap forward would be of particular interest includes patients over age 70, those who have received immune altering systemic management for a co-morbidity or for patients whose medication requirements up until now would have eliminated them from a regenerative consideration.

To learn more schedule an appointment 847 390 7666

You may access my web site and watch my Webinar at www.Ilcellulartherapy.com

Tags: , , , , , ,

Pin It on Pinterest

Share This